Pandemic Preparedness & Disease X (UPSC Science & Tech)

“Disease X” is the WHO’s placeholder term for the next unknown pathogen that could cause a serious international epidemic. The COVID-19 pandemic proved that such a disease is not science fiction — and next time it could be worse. India, scarred by 2020-22, is now investing in surveillance, vaccines, hospital capacity, one-health coordination and global governance reforms. For UPSC, this is a frequently-tested topic across GS Paper III (Science & Tech, Disaster Management) and GS Paper II (Health Governance, International Relations).

What is Disease X?

The WHO's R&D Blueprint Priority Pathogens list identifies diseases with epidemic potential but limited or no counter-measures — including Ebola, Marburg, Lassa, Nipah, MERS-CoV, SARS, Crimean-Congo hemorrhagic fever, Rift Valley fever, and "Disease X", a reserved slot for an unknown future threat.

Disease X characteristics assumed:

• Zoonotic origin — from bats, rodents, primates or livestock.
• Respiratory or vector-borne transmission.
• High R₀ — rapid human-to-human spread.
• Case fatality ratio uncertain (could be much higher than SARS-CoV-2).
• No existing vaccine, limited diagnostics.

Candidates often discussed: a novel influenza strain (H5N1 reassortant), another sarbecovirus, a new henipavirus, prion, or antifungal-resistant fungus.

Drivers of spill-over and spread

Lessons from COVID-19 (2019-23)

• Speed of science: mRNA vaccines developed in 11 months from genome to deployment.
• Global scale-up: Serum Institute became backbone of COVAX via Covishield and Covovax.
• Diagnostics: RT-PCR and rapid antigen testing scaled rapidly.
• Digital platforms: CoWIN (India), Aarogya Setu — mass public-health infra.
• INSACOG consortium — India's genomic surveillance of SARS-CoV-2.
• Failures: oxygen shortage in Delta wave, vaccine nationalism, data opacity.
• Cost: IMF estimated COVID set back global GDP by $28 trillion.

India's pandemic-preparedness architecture

Institutional

Legal

• Epidemic Diseases Act, 1897 (colonial); inadequate for modern challenges.
• Disaster Management Act, 2005 — main legal basis used in COVID-19.
• Drugs & Cosmetics Act, 1940; New Drugs and Clinical Trials Rules 2019.
• IT Rules and DPDP Act 2023 — for data aspects of digital health.
• Ayushman Bharat Digital Mission (ABDM) — digital health infrastructure.

Vaccines

• Mission Indradhanush / PMSM — routine immunisation.
• Universal Immunization Programme — 12 vaccines.
• Serum Institute of India — world's largest volume vaccine maker.
• Bharat Biotech, Biological E, Zydus, Panacea, Shantha — vaccine manufacturing depth.
• CEPI partnerships — pandemic prep funding.
• mRNA vaccine platforms — Gennova (HGCO19, approved 2022); scaling up.

Surveillance and diagnostics

• INSACOG — genomic sequencing for SARS-CoV-2 and expanding to other pathogens.
• IDSP and Integrated Health Information Platform (IHIP) — real-time surveillance.
• National Institute of One Health (NIOH), Nagpur — opened 2022.
• BSL-3 and BSL-4 labs — NIV Pune's BSL-4 is South Asia's only public BSL-4.
• ICMR's National Biosafety Support Unit.

Global governance

Present

• IHR 2005 — mandates reporting of public health emergencies of international concern (PHEIC).
• WHO — declares PHEIC (COVID-19, mpox 2022 & 2024).
• GPMB (Global Preparedness Monitoring Board) — annual report.
• Gavi, CEPI, FIND, UNICEF — pandemic infrastructure partners.
• Global Health Security Agenda (GHSA) — multilateral platform.

Emerging

• Pandemic Agreement (WHO) — negotiations began 2022 after COVID-19; targeted completion postponed; WHA 77 (May 2024) extended talks to WHA 78 (May 2025). Key issues: pathogen and benefit sharing, technology transfer, equitable access (PABS — Pathogen Access and Benefit-Sharing system), sovereignty concerns.
• IHR 2005 Amendments (June 2024) adopted: pandemic emergencies classification, equitable access provisions, financing mechanisms.
• Pandemic Fund (World Bank, 2022) — disburses for LMIC preparedness.

India's position

India has:

• Supported strong IHR amendments.
• Pushed for pathogen-sharing linked to benefit-sharing.
• Hosted One Health Leaders' Meeting during G20 Presidency (2023).
• Opposed extraterritorial WHO authority that could violate sovereignty.

One Health in India

• National One Health Mission (2023) — ICMR, DBT, MoEFCC, DAHD, MoHFW coordination.
• Cross-sectoral triggers: monitoring zoonoses, AMR, food safety, wildlife pathogens.
• National Institute of One Health (Nagpur) as a hub.
• ICMR's Bhopal Memorandum (2023) — One Health framework.

Key diseases to watch

Innovation frontier

• mRNA platform vaccines — rapid design for new pathogens.
• Self-amplifying RNA (saRNA) vaccines.
• Pan-coronavirus vaccines.
• AI-based pathogen surveillance — wastewater sequencing, social media signals.
• Metagenomic sequencing for unknown agents.
• Phage therapies for resistant bacteria.
• Broad-spectrum antivirals.
• CRISPR-based diagnostics (Sherlock, DETECTR, FELUDA — CSIR-IGIB's FELUDA approved for COVID in 2020).

Latest developments (2024-26)

• WHO IHR amendments adopted (June 2024) — pandemic emergency concept, equitable access, financing.
• Pandemic Agreement (2025) — target finalisation at WHA 78 (May 2025); key issues unresolved on PABS.
• Mpox PHEIC (Aug 2024) — clade Ib spread from DRC to multiple countries; India reported first case of clade Ib in early 2025.
• H5N1 in US dairy cattle (2024-25) — global surveillance stepped up.
• Marburg virus Rwanda outbreak (2024) — containment with emergency vaccines.
• PM-ABHIM implementation — 70%+ of district labs operationalised by 2024.
• Project BIRD (ICMR) — biobanking for pathogen readiness.
• National One Health Mission rolled out (2024).
• Bharat Biotech's Chandipura/Nipah vaccine candidates under development (2024-25).
• AI Action Summit, Paris (Feb 2025) — AI-for-pandemic flagged.
• India Semiconductor Mission — diagnostic chip manufacturing.
• DeepTech Policy 2024 — biosensors, vaccine manufacturing.
• National Quantum Mission (2024) — quantum sensors for pathogen detection.
• Chandrayaan-4 plan and Gaganyaan progress — space-biology research in microbial resilience.

UPSC Relevance

GS Paper III — Science & Technology / Health

• Pandemic preparedness, Disease X, vaccines.

GS Paper II — Governance / International Relations

• WHO reforms, IHR, Pandemic Agreement.

GS Paper III — Disaster Management

• DM Act 2005, multi-sectoral coordination.

GS Paper II — Social Justice

• Equitable access, PDS-style vaccine distribution.

GS Paper IV — Ethics

• Vaccine nationalism; prioritising vulnerable; clinical-trial ethics.

Prelims pointers — WHO R&D Blueprint Priority Pathogens, INSACOG, PM-ABHIM (Rs 64,180 crore), IHR 2005, Pandemic Agreement, Mpox PHEIC 2024, One Health Mission, Ayushman Bharat Digital Mission, NIV Pune BSL-4.

Interview probes — lessons from COVID; pandemic treaty sovereignty issues; One Health; district-level preparedness; mpox vs COVID response.

Disease X is not a matter of "if" but "when". The test of a public-health state is whether its next wave arrives faster than its last bureaucratic memo. India is building that muscle — slowly but deliberately.

PDF